bluebird bio (BLUE) Misses Q4 EPS by 10c

bluebird bio (NASDAQ: BLUE) reported Q4 EPS of ($0.67), $0.10 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.2 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Corona-maker Constellation Brands beats estimates, shares jump 2%
• Constellation Brands (STZ) Tops Q1 EPS by 18c